Early triple antiviral therapy for COVID-19

Nelson Lee, Michael Ison, William Dunning

Research output: Contribution to journalLetterpeer-review

4 Citations (Scopus)
Original languageEnglish
Pages (from-to)1487-1488
Number of pages2
JournalThe Lancet
Volume396
Issue number10261
DOIs
Publication statusPublished - 7 Nov 2020

Bibliographical note

Funding Information:
NL reports non-financial support from Shionogi; personal fees and non-financial support from Janssen Pharmaceuticals, Roche, and Sanofi Pasteur; personal fees and other support from Gilead Sciences and Genetech; and personal fees from Cidara Therapeutics, outside the submitted work. MI reports grants from AiCuris and Shire; grants, personal fees, and other support from Janssen; personal fees and other support from Allovir; personal fees from Celltrion, Roche, Shionogi, Viracor Eurofins; and other support from Merck, Sequiris, Takeda, Vitaeris, SAB Biotherapeutics, outside the submitted work. JD declares no competing interests.

Cite this